IBM®
Skip to main content
    Country/region [change]    Terms of use
 
 
 
    Home    Products    Services & solutions    Support & downloads    My account    

IBM Systems Journal
Business Innovation   Volume 44, Number 1, 2005
Table of contents: HTMLPDF This article: HTMLPDF   Copyright info

A model-driven approach to industrializing discovery processes in pharmaceutical research - References

 by K. Bhattacharya,
R. Guttman,
K. Lyman,
F. F. Heath III,
S. Kumaran,
P. Nandi,
F. Wu,
P. Athma,
C. Freiberg,
L. Johannsen,
and A. Staudt
Cited references and notes

  1. J. A. DiMasi, R. W. Hansen, H. G. Grabowski, and L. Lasagna, “Cost of Innovation in the Pharmaceutical Industry,” Journal of Health Economics 10, No. 2, 107–142 (1991).
  2. S. Arlington, Pharma 2005: An industrial revolution in R & D, http://www-1.ibm.com/services/us/imc/pdf/gw510-9220-pharma-2005-industrial-revolution.pdf.
  3. S. J. Arlington, S. Barnett, S. Hughes, and J. Palo, “Pharma 2010—The Threshold of Innovation,” The Future of the Pharmaceutical Industry, IBM Corporation (2004), http://www-1.ibm.com/services/us/index.wss/xs/imc/a1001099?cntxtld=a1000060.
  4. J. R. Archer, “Faculty or Factory? Why Industrialized Drug Discovery Is Inevitable,” Journal of Biomolecular Screening 4, No. 5, 235–237 (1999).
  5. T. Peakman, S. Franks, C. White, and M. Beggs, “Delivering the Power of Discovery in Large Pharmaceutical Organizations,” Drug Discovery Today 8, No. 5, 203–211 (March 2003).
  6. S. Kumaran, “Model-Driven Enterprise,” Proceedings of the Global Enterprise Application Integration (EAI) Summit 2004, Banf, Canada (2004), pp. 166–180.
  7. R. S. Kaplan and D. P. Norton, “The Balanced Scorecard—Measures that Drive Performance,” Harvard Business Review, 71–79 (January-February 1992).
  8. WebSphere Business Integration Modeler, IBM Corporation, http://www.ibm.com/software/integration/wbimodeler/.
  9. S. Kumaran and P. Nandi, “Adaptive Business Objects: A New Component Model for Business Applications,” in preparation.
  10. Unified Modeling Language, Object Management Group, http://www.uml.org/.
  11. K. Vredenburg, S. Isensee, and C. Righi, User-Centered Design: An Integrated Approach, Prentice-Hall, , Upper Saddle River, NJ (2002).
  12. M. Beggs, “HTS—where next?”, Drug Discovery World 2, 25–30 (2000).
  13. M. Beggs and A. C. Long, “High Throughput Genomics and Drug Discovery—Parallel Universes or a Continuum?”, Drug Discovery World 3, 75–80 (2002).
  14. A. Nigam and N. S. Caswell, “Business Artifacts: An Approach to Operational Specification,” IBM Systems Journal 42, No. 3, p. 428–445 (2003).
  15. J. E. Hanson, P. Nandi, and S. Kumaran, “Conversation Support for Business Process Integration,” IEEE International Enterprise Distributed Object Conference (EDOC), 65–74 (2002).
  16. The J2EE Connector Architecture's Resource Adapter, Sun Microsystems, Inc., http://java.sun.com/developer/technicalArticles/J2EE/connectorclient/resourceadapter.html.
  17. In the future we will make use of a more flexible and powerful approach using Service Data Objects (SDO) (see Service Data Objects, IBM Corporation and BEA Systems, Inc. (2003), Java Community Process, http://www.jcp.org/en/jsr/detail?id=235).
  18. Lotus Workplace Products, IBM Corporation, http://www.lotus.com/products/product5.nsf/wdocs/workplacehome.
  19. A demo and screenshots of the solution are available upon request from the first author.
  20. Business Processes Definition Metamodel: Concepts and Overview, Object Management Group, http://www.omg.org/docs/bei/04-05-03.pdf.
  21. Eclipse Modeling Framework, Eclipse Foundation, http://www.eclipse.org/emf/.
  22. L. M. Haas, E. T. Lin, and M. A. Roth, “Data Integration Through Database Federation,” IBM Systems Journal 41, No. 4, 578–596 (2002).
  23. N. Davis and T. Peakman, “Making the Most of Your Discovery Data,” Drug Discovery World, 17–23 (April 2004).


    About IBM    Privacy    Contact